PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 9/20, 31/12, 31/16 — A1

(11) International Publication Number: WO 00/15196

(43) International Publication Date: 23 March 2000 (23.03.00)

(21) International Application Number: PCT/FI99/00740

(22) International Filing Date: 13 September 1999 (13.09.99)

(30) Priority Data:
09/152,263 14 September 1998 (14.09.98) US

(71) Applicant *(for all designated States except US)*: ORION CORPORATION [FI/FI]; Orionintie 1, FIN–02200 Espoo (FI).

(72) Inventor; and
(75) Inventor/Applicant *(for US only)*: VAHERVUO, Kari [FI/FI]; Maininkitie 3 C 11, FIN–02320 Espoo (FI).

(74) Agent: ORION CORPORATION; Orion Pharma, Industrial Property Rights, P.O. Box 65, FIN–02101 Espoo (FI).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: PHARMACEUTICAL COMPOSITION COMPRISING ENTACAPONE OR NITECAPONE AS WELL AS A CROSS–LINKED CELLULOSE DERIVATIVE

(57) Abstract

The present invention relates to an oral compacted composition comprising entacapone, nitecapone, or a pharmaceutically acceptable salt thereof and a cross–linked cellulose derivative. The composition is premised on the discovery that the cross–linked cellulose derivative increases the release rate of entacapone or nitecapone from an oral compacted composition. Preferably the amount of the cross–linked cellulose derivative in the composition is at least 6 % by weight, preferably from about 8 % to about 16 % weight, especially from about 10 % to about 14 % by weight.